Mechanism of Action
Amylin Receptor Signaling
IAPP/amylin activates amylin receptors, which are heterodimers of the calcitonin receptor (CTR) and receptor activity-modifying proteins (RAMP1, 2, or 3). These Gs-coupled receptors are highly expressed in the area postrema and hypothalamus. Activation reduces postprandial glucagon secretion, slows gastric emptying to reduce glucose absorption rate, and signals satiety to reduce meal size.
Beta-Cell Amyloid Toxicity
Human IAPP has an amyloidogenic region (residues 20-29) that forms beta-sheet aggregates under the high local concentrations found in beta-cell secretory granules. Amyloid fibrils disrupt beta-cell membranes through both pore-forming and apoptotic mechanisms, contributing to the progressive beta-cell loss characteristic of type 2 diabetes. Pramlintide contains proline substitutions in this region that prevent aggregation.
Research Summary
Pramlintide in Type 1 and Type 2 Diabetes
FDA ApprovedPramlintide (Symlin) is FDA-approved as an adjunct to mealtime insulin in type 1 and type 2 diabetes. Clinical trials demonstrate 0.3-0.6% HbA1c reduction, significant postprandial glucose lowering, and 1-2 kg weight loss over 6 months. The main limitation is the requirement for separate injection at mealtimes and risk of hypoglycemia requiring insulin dose adjustment.
Alzheimer Disease Connection
PreclinicalIAPP amyloid and Alzheimer amyloid (Abeta) share structural properties and may cross-seed each other. Type 2 diabetic patients have increased Alzheimer risk, and IAPP/amylin signaling in the brain modulates cognitive function. Amylin receptor activation in the hippocampus may have neuroprotective effects, and amylin analogs are being explored in Alzheimer disease models.
Calculate your IAPP dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Pramlintide, Type 1 DM | 15-60 mcg | With meals (3x/day) | Subcutaneous injection |
| Pramlintide, Type 2 DM | 60-120 mcg | With meals (3x/day) | Subcutaneous injection |
Pramlintide must be given separately from insulin (different syringe). Reduce meal insulin by 50% when initiating.
Interactions
Safety Profile
Pramlintide carries a boxed warning for insulin-induced severe hypoglycemia. Nausea is the most common adverse effect (up to 40%), typically improving after 4-8 weeks. Injection site reactions occur but are mild. Anorexia and weight loss are beneficial side effects for most patients. No pancreatitis signal unlike GLP-1 agonists.
References
- [1]Cooper GJ et al. (1987). Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. PNAS, 84(23), 8628-8632.
- [2]Ratner RE et al. (2004). Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus. Diabetic Medicine, 21(11), 1204-1212.